Avadel Pharmaceuticals (AVDL) Projected to Post Earnings on Thursday

Key Points

• Avadel Pharmaceuticals is expected to announce its Q2 2025 earnings on Thursday, August 7th, with anticipated earnings of $0.02 per share and revenue of $60.28 million.
• The company reported a revenue increase of 93.2% year-over-year in its last quarterly earnings, exceeding analysts' expectations.
• Research analysts maintain a "buy" rating on Avadel Pharmaceuticals, with an average target price of $18.33 per share.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Avadel Pharmaceuticals to post earnings of $0.02 per share and revenue of $60.28 million for the quarter. Avadel Pharmaceuticals has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02. Avadel Pharmaceuticals had a negative return on equity of 36.07% and a negative net margin of 13.58%. The company had revenue of $52.51 million for the quarter, compared to analyst estimates of $50.57 million. During the same quarter in the prior year, the firm posted ($0.30) EPS. Avadel Pharmaceuticals's quarterly revenue was up 93.2% compared to the same quarter last year. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avadel Pharmaceuticals Trading Down 0.6%

NASDAQ:AVDL traded down $0.07 during midday trading on Tuesday, hitting $11.20. 180,616 shares of the company traded hands, compared to its average volume of 1,325,501. The firm's fifty day moving average is $9.82 and its 200-day moving average is $8.79. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $17.30. The firm has a market capitalization of $1.08 billion, a P/E ratio of -41.46 and a beta of 1.47.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Avadel Pharmaceuticals stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,885 shares of the company's stock after purchasing an additional 2,291 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.06% of Avadel Pharmaceuticals worth $430,000 as of its most recent SEC filing. Institutional investors own 69.19% of the company's stock.

Wall Street Analyst Weigh In

AVDL has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Avadel Pharmaceuticals in a research report on Friday, July 18th. Needham & Company LLC reissued a "buy" rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $18.33.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.